Chemomab Secures FDA Alignment for Single Pivotal Phase 3 Trial of Nebokitug in PSC, Extends Cash Runway

summarizeSummary

Chemomab Therapeutics announced successful FDA alignment for a single pivotal Phase 3 trial of nebokitug in PSC, a significant de-risking event, alongside financial results extending its cash runway through Q1 2027.

check_boxKey Events

• FDA Alignment on Phase 3 Design for Nebokitug

  The company completed a successful End-of-Phase 2 meeting with the FDA, achieving alignment on a clear and efficient pathway for potential regulatory approval of nebokitug in Primary Sclerosing Cholangitis (PSC) based on a single pivotal Phase 3 trial. The trial will use a primary composite endpoint of well-characterized clinical events associated with disease progression.

• Extended Cash Runway

  Chemomab reported cash, cash equivalents, and short-term bank deposits of $10.4 million as of December 31, 2025. This cash position is expected to fund operations through the end of the first quarter of 2027.

• Positive Phase 2 Data Reinforcement

  Results from the Phase 2 SPRING trial for nebokitug in PSC were published in the American Journal of Gastroenterology and featured in multiple scientific presentations, reinforcing its positive safety profile and disease-modifying potential.

• Advancing Strategic Partner Discussions

  Discussions with potential strategic partners are continuing to advance as the company progresses activities required for the timely initiation of the Phase 3 trial in PSC.

auto_awesomeAnalysis

Chemomab Therapeutics has achieved a critical milestone by securing FDA alignment on a clear and efficient pathway for nebokitug's Phase 3 trial in Primary Sclerosing Cholangitis (PSC). This agreement for a single pivotal trial, utilizing a clinical event-driven composite endpoint, significantly de-risks the development program and provides a streamlined path towards potential regulatory approval. For a clinical-stage biotech, this regulatory clarity is a major positive catalyst. Additionally, the company has extended its cash runway through the first quarter of 2027, providing financial stability to advance its lead program.